Biotech News

Sana Biotechnology to Present at December 2025 Investor Conferences

Sana Biotechnology (SANA)Sana Biotechnology2026-06-25 13:46 ESTConference / presentation

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December.

Open original release

Related news

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at March 2026 Investor Conferences

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

View all latest news

Sana Biotechnology

Sana Biotechnology is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SANAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

SANAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

SANABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

SANAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

SANAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 3.64 USD
Market cap: 1.07B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States